secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pelthos Therapeutics Inc. (PTHS)
CIK:        0001919246
Form:       8-K/A
Filed at:   2025-09-16T23:59:59+00:00
Accession:  0001753926-25-001500
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 9.01, 2.01, 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Pelthos (PTHS) files LNHC unaudited financials and pro forma data post-merger closed July 1, 2025
--------------------------------------------------------------------------------

- Merger closed July 1, 2025; issued ~31,278 Series A Preferred shares to Ligand; PIPE raised ~$50.1M gross.
- LNHC unaudited balance sheets as of June 30, 2025 and 2024; pro forma financial info provided for combined entity.
- ZELSUVMI (berdazimer gel) FDA approved Jan 2024 for molluscum contagiosum; 13% royalty to Ligand on worldwide sales.
- Nomis RoyaltyVest receives 1.5% royalty on ZELSUVMI net sales; additional royalty agreements with Ligand and Madison.
- Company holds exclusive license from Ligand for ZELSUVMI ex-Japan; 19,265 sq ft facility in Durham, NC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1919246/000175392625001500/0001753926-25-001500-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1919246/000175392625001500/g084946_8-ka.htm
  HTML page:      https://secwatch.observer/filing/0001753926-25-001500

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer